Enlivex Therapeutics schedules annual general meeting for November 10

Published 25/09/2025, 21:44
© Enlivex Therapeutics PR

Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a biotechnology company with current revenues of $4.83 million and an InvestingPro Financial Health rating of FAIR, announced Thursday that it will hold its Annual General Meeting of Shareholders on Monday, November 10, 2025, at 7:00 p.m. Israel time. The meeting will take place at the company’s offices located at 14 Einstein Street, Nes Ziona, Israel.

The company provided notice of the meeting and a proxy statement, along with a form of proxy card, as attachments to its latest filing with the U.S. Securities and Exchange Commission. Details regarding the agenda and matters to be voted on were not included in Thursday’s announcement but are available in the referenced documents.

This information is based on a press release statement included in Enlivex Therapeutics’ recent SEC filing.

In other recent news, Mega Matrix Inc. announced that its shareholders have approved significant changes to the company’s share capital structure. At an Extraordinary General Meeting in Singapore, a resolution was passed to increase the authorized share capital to $1,110,000. This adjustment includes the addition of 900,000,000 class A ordinary shares and 40,000,000 class B ordinary shares, along with the creation of 50,000,000 new class C ordinary shares. The company also introduced 10,000,000 preferred shares, all with a par value of $0.001 each. Meanwhile, B.O.S. Better Online Solutions Ltd. has scheduled its annual shareholder meeting for October 23, 2025. The company has released its proxy statement and form of proxy card in connection with the meeting, though the specific matters to be discussed or voted upon have not been disclosed. These developments reflect ongoing strategic moves by both companies in their corporate governance and capital management efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.